Breast Cancer Research and Treatment

, Volume 89, Issue 3, pp 265–270 | Cite as

Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments

  • Anat AchironEmail author
  • Yoram Barak
  • Mitchell Gail
  • Matilda Mandel
  • David Pee
  • Rajeev Ayyagari
  • Zeev Rotstein


Multiple sclerosis (MS) has been linked to reduced rates of cancer prior to the era of immunomodulating treatments. We assessed the incidence of cancer in a cohort of 1338 MS patients and evaluated the effect of exposure to immunomodulatory treatment. Cancer incidence in the MS population was compared with the expected age- and gender-matched incidence rates in the Israeli population for the period 1960–2003. Time-dependant Cox model analysis was used to estimate hazard ratios for glatiramer acetate, β-interferons (1a and 1-b) and intravenous immunoglobulins (IVIg). Among 892 female MS patients, 15 (1.7%) developed breast cancer, and 31 (3.5%) developed cancers of any type. Seventeen of 446 (3.8%) male MS patients developed cancer. The standardized incidence ratios (SIRs) computed until the time of first immunomodulatory treatment were 0.60 (95% CI, 0.38–0.92, p = 0.02) for all female cancer, and 1.11 (95% CI, 0.64–1.91) for all male cancer. Time-dependent covariate analyses for female breast cancer yielded a relative risk for glatiramer acetate of 3.10 (95% CI, 0.86–11.1) and 0.52 (95% CI, 0.07–4.05) for β-interferons. For IVIg, the analyses were uninformative. Our findings indicate that cancer incidence is significantly lower in female MS patients than in the general population. Female MS patients treated with glatiramer acetate showed an elevated rate of breast cancer and all MS patients treated with β-interferons showed an elevated risk of non-breast cancers though not statistically significant (p = 0.122 and 0.072, respectively). Further study is needed to assess possible associations between long-term exposure to the novel immunomodulatory treatments in MS and rate of caner.


breast cancer cancer immunomodulatory drugs multiple sclerosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ottenhoff, TH 1996Selective modulation of T-cell responses in autoimmunity and cancerImmunol Today175455PubMedGoogle Scholar
  2. Tomer, Y, Sherer, Y, Shoenfeld, Y 1998Autoantibodies, autoimmunity and cancerOncol Rep5753761PubMedGoogle Scholar
  3. Shoenfeld Y, Gershwin ME (eds): Cancer and Autoimmunity. Elsevier publications, 2000, pp 19–111.Google Scholar
  4. Lewis, RB, Castor, CW, Knisley, RE, Bole, GG 1976Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritisArthritis Rheum1912561260PubMedGoogle Scholar
  5. Mellemkjaer, L, Andersen, V, Linet, MS, Gridley, G, Hoover, R, Olsen, JH 1997Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosusArthritis Rheum40761768PubMedGoogle Scholar
  6. Xu, Y, Wiernik, PH 2001Systemic lupus erythematosus and B-cell hematologic neoplasmLupus10841850PubMedGoogle Scholar
  7. Rosenthal, AK, McLaughlin, JK, Gridley, G, Nyren, O 1995Incidence of cancer among patients with systemic sclerosisCancer76910914PubMedGoogle Scholar
  8. Canoso, JJ, Cohen, AS 1974Malignancy in a series of 70 patients with systemic lupus erythematosusArthritis Rheum17383390PubMedGoogle Scholar
  9. Lopez Dupla, M, Khamashta, M, Pintado Garcia, V, Lavilla Uriol, P, Valencia Ortega, E, Gil Aguado, A 1993Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patientsLupus2377380PubMedGoogle Scholar
  10. Mutru, O, Laakso, M, Isomaki, H, Koota, K 1985Ten year mortality and causes of death in patients with rheumatoid arthritisBr Med J29017971799CrossRefGoogle Scholar
  11. Thomas, E, Brewster, DH, Black, RJ, Macfarlane, GJ 2000Risk of malignancy among patients with rheumatic conditionsInt J Cancer88497502PubMedGoogle Scholar
  12. Wolfe, F, Mitchell, DM, Sibley, JT, Fries, JF, Bloch, DA, Williams, CA, Spitz, PW, Haga, M, Kleinheksel, SM, Cathey, MA 1994The mortality of rheumatoid arthritisArthritis Rheum37481494PubMedGoogle Scholar
  13. Jacobsen, S, Halberg, P, Ullman, S 1998Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma)Br J Rheumatol37750755PubMedGoogle Scholar
  14. Hughes, GRV 2001Lupus patients are protected from cancerLupus10833834PubMedGoogle Scholar
  15. Achiron, A, Barak, Y 2000Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective studyArch Neurol.57974979PubMedGoogle Scholar
  16. Cohen, IR 2000Discrimination and dialogue in the immune systemSemin Immunol12215219PubMedGoogle Scholar
  17. Allen, IV, Millar, JH, Hutchinson, MJ 1978General disease in 120 necropsy-proven cases of multiple sclerosisNeuropathol Appl Neurobiol4279284CrossRefPubMedGoogle Scholar
  18. Koch-Henriksen, N, Bronnum-Hansen, H, Stenager, E 1998Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis RegistryJ Neurol Neurosurg Psychiatry655659PubMedGoogle Scholar
  19. Sadovnick, AD, Eisen, K, Ebers, GC, Paty, DW 1991Cause of death in patients attending multiple sclerosis clinicsNeurology4111931196PubMedGoogle Scholar
  20. Midgard, R, Glattre, E, Gronning, M, Riise, T, Edland, A, Nyland, H 1996Multiple sclerosis and cancer in Norway. A retrospective cohort study Acta Neurol Scand93411415PubMedCrossRefGoogle Scholar
  21. Moller, H, Kneller, RW, Boice, JD, Olsen, JH 1991Cancer incidence following hospitalization for multiple sclerosis in DenmarkActa Neurol Scand84214220PubMedCrossRefGoogle Scholar
  22. Palo, J, Duchesne, J, Wikstrom, J 1977Malignant diseases among patients with multiple sclerosisJ Neurol216217222PubMedGoogle Scholar
  23. Percy, AK, Nobrega, FT, Okazaki, H, Glattre, E, Hurland, T 1971Multiple sclerosis in Rochester, Minn. A 60-year appraisalArch Neurol25105111PubMedGoogle Scholar
  24. Bronnum-Hansen, H, Koch-Henriksen, N, Stenager, E 2004Trends in survival and cause of death in Danish patients with multiple sclerosisBrain127844850PubMedGoogle Scholar
  25. Goodin, DS, Frohman, EM, Garmany, GP,Jr, Halper, J, Likosky, WH, Lublin, FD, Silberberg, DH, Stuart, WH, van den Noort, S 2002Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesNeurology58169178PubMedGoogle Scholar
  26. Poser, CM, Paty, DW, Scheinberg, L, McDonald, WI, Davis, FA, Ebers, GC, Johnson, KP, Sibley, WA, Silberberg, DH, Tourtellotte, WW 1983New diagnostic criteria for multiple sclerosis: guidelines for research protocolsAnn Neurol13227231PubMedGoogle Scholar
  27. Gail, MH 1981Evaluating serial cancer marker studies in patients at risk of recurrent diseaseBiometrics376778PubMedGoogle Scholar
  28. Cox, DR 1972Regression models and life tables (with discussion)J Roy Statist Soc B34187220Google Scholar
  29. Central Bureau of Statistics, Israel: Census of Population and Housing; Publication No. 1, Population and Households, pp 2–74, table 2.23, 2002.Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Anat Achiron
    • 1
    • 4
    Email author
  • Yoram Barak
    • 1
  • Mitchell Gail
    • 2
  • Matilda Mandel
    • 1
  • David Pee
    • 3
  • Rajeev Ayyagari
    • 3
  • Zeev Rotstein
    • 1
  1. 1.Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Sacker School of MedicineTel Aviv UniversityTel-AvivIsrael
  2. 2.Biostatistics Branch, Division of Cancer Epidemiology and Genetics National Cancer InstituteBethesdaUSA
  3. 3.Information Management ServicesRockvilleUSA
  4. 4.Multiple Sclerosis CenterSheba Medical CenterTel-Hashomer Israel

Personalised recommendations